Get the Stockscreener App
1.66
1.19%
-0.02
Aldeyra Therapeutics Inc stock is traded at $1.66, with a volume of 1.81M.
It is down -1.19% in the last 24 hours and down -70.46% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.68
Open:
$1.69
24h Volume:
1.81M
Relative Volume:
0.67
Market Cap:
$99.90M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.9443
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-9.78%
1M Performance:
-70.46%
6M Performance:
-68.80%
1Y Performance:
-68.83%
1-Day Range:
$1.63
$1.72
1-Week Range:
$1.63
$1.87
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.66 | 99.90M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - sahmcapital.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Shareholders who lost money in Aldeyra Therapeutics, Inc. - GlobeNewswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
2026-04-03 | ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ALDX | Press Release - Stockhouse
ROSEN Attorneys Encourage Aldeyra Therapeutics Investors to Secure Counsel - nationaltoday.com
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra - GlobeNewswire
ADLX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Aldeyra Therapeutics, Inc. - PR Newswire
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) ... - Bluefield Daily Telegraph
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming DeadlinesALDX - PR Newswire
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX SEC FilingsAldeyra Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BTIG Maintains ALDX (Aldeyra Therapeutics) at Buy on Mar 17, 2026 - Meyka
Aldeyra Therapeutics, Inc. 8-K SEC Filing April 2026 – Company Information, Address, and Trading Details - Minichart
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Aldeyra Therapeutics pays off $15 million outstanding borrowings, terminates Hercules credit facilitySEC filing - MarketScreener
Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit FacilitySEC Filing - TradingView
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility - TipRanks
Aldeyra Therapeutics repays $15 million Hercules loan and ends credit facility - Investing.com
Aldeyra pays off $15M loan, terminates Hercules credit facility - TradingView
Aldeyra (NASDAQ: ALDX) pays off $15M Hercules loan, extends runway - Stock Titan
Aldeyra Therapeutics, Inc. Pays Off $15 Million Outstanding Borrowings and Terminates Hercules Credit Facility - MarketScreener
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Malaysian Reserve
INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therap - GuruFocus
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - bastillepost.com
Aldeyra (NASDAQ: ALDX) grants CEO 1.88M options and bonus units - Stock Titan
Aldeyra Therapeutics Sued for Securities Fraud - nationaltoday.com
Lawsuit Filed Against Aldeyra Therapeutics Over Clinical Trial Inconsistencies - nationaltoday.com
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Class Action Lawsuit Filed Against Aldeyra Therapeutics - nationaltoday.com
2026-03-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation | NDAQ:ALDX | Press Release - Stockhouse
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact ... - Bluefield Daily Telegraph
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for - GlobeNewswire
Robbins LLP Informs Investors of Aldeyra Therapeutics Class Action - nationaltoday.com
Investor Notice: Robbins LLP Informs Investors of the Aldeyra Therapeutics, Inc. Class Action - marketscreener.com
Rosen Law Firm Files Securities Class Action Lawsuit Against Aldeyra Therapeutics - nationaltoday.com
ALDX Forecast, Price Target & Analyst Ratings | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ROSEN Law Firm Encourages Aldeyra Therapeutics Investors to Seek Legal Counsel - nationaltoday.com
Rosen Law Firm Files Securities Class Action Against Aldeyra Therapeutics - nationaltoday.com
Value Recap: Can Aldeyra Therapeutics Inc maintain sales growth2026 Technical Patterns & Fast Gain Swing Trade Alerts - baoquankhu1.vn
ROSEN, LEADING INVESTOR COUNSEL, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):